The study was not set up to look at any differences between the two. The Pfizer/BioNTech was available first so there is more data, but the Oxford/AstraZeneca was mostly used in the older age group. The numbers were very small and there was uncertainty over their significance, said the researchers. The study, released as a preprint ahead of peer review, is hosted on the University of Edinburgh website (bit.ly/3aHQXzh), and has been uploaded to the SSRN preprint site, according to a University statement. That rose to more than 85% after the second dose.
The Pfizer/ BioNTech is comfortable for use.
( z0 comfortable :purpose ( z1 use ) :ARG0 ( z2 slash :op ( z3 company :name ( z4 name :op "Pfizer" ) ) :op ( z5 company :name ( z6 name :op "BioNTech" ) ) ) )
(z0 / comfortable-02
    :purpose (z1 / use-01)
    :ARG0 (z2 / slash
              :op1 (z3 / company
                       :name (z4 / name
                                 :op1 "Pfizer"))
              :op2 (z5 / company
                       :name (z6 / name
                                 :op1 "BioNTech"))))
The Pfizer / BioNTech is comfortable for use .
z3 :name z4
z4 :op1 1
z2 :op1 z3
z2 :op2 z5
z5 :name z6
z6 :op1 0
z0 :ARG0 z2
z0 :purpose z1